Pharmacy Articles

Pharmacy

sponsor

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Hogue JC et al. - The specific impact of 3-hydroxy-3-methylglutaryl–coenzyme A reductase inhibitors and fibrates on the in vivo metabolism of apolipoprotein (apo) B has not been systematically investigated in patients with type 2 diabetes mellitus with high plasma triglyceride (TG) levels. Therefore, the objective of this 2-group parallel study was to examine the differential effects of a 6-week treatment with atorvastatin or fenofibrate on in vivo kinetics of apo B-48 and B-100 in men with type 2 diabetes mellitus with marked hypertriglyceridemia

Related Articles

Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies
Diabetic Medicine, 11/25/09    Relevance Score: 90%

Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus
Journal of Clinical Endocrinology and Metabolism, 11/10/09    Relevance Score: 90%

Evidence for an association with type 2 diabetes mellitus at the PPARG locus in a South Indian population
Metabolism-Clinical and Experimental, 11/03/09    Relevance Score: 90%

Hepatic fat and inflammation in type 2 diabetes mellitus
Metabolism-Clinical and Experimental, 10/26/09    Relevance Score: 90%

Design of a family-based lifestyle intervention for youth with type 2 diabetes: the TODAY study
International Journal of Obesity, 10/16/09    Relevance Score: 90%

Today in Other Drugs...keeping you current

New central targets for the treatment of obesity
British Journal of Clinical Pharmacology, 12/11/09

Metformin increases plasma ghrelin in Type 2 diabetes
British Journal of Clinical Pharmacology, 12/11/09

Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation
Core Evidence, 12/11/09